Simcere Pharmaceutical Group. (SCR) Misses Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts SCR Hot Sheet
Join SI Premium – FREE
Simcere Pharmaceutical Group. (NYSE: SCR) reported Q1 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $73.6 million versus the consensus estimate of $79.37 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
- XP Inc. (XP) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
